A Randomized Controlled Trial Comparing the Effects of Counseling and Alarm Device on HAART Adherence and Virologic Outcomes
Background:
Behavioral interventions that promote adherence to antiretroviral medications may decrease HIV treatment failure. Antiretroviral treatment programs in sub-Saharan Africa confront increasing financial constraints to provide comprehensive HIV care, which include adherence interventions. This study compared the impact of counseling and use of an alarm device on adherence and biological outcomes in a resource-limited setting.
Methods and Findings:
A randomized controlled, factorial designed trial was conducted in Nairobi, Kenya. Antiretroviral-naïve individuals initiating free highly active antiretroviral therapy (HAART) in the form of fixed-dose combination pills (d4T, 3TC, and nevirapine) were randomized to one of four arms: counseling (three counseling sessions around HAART initiation), alarm (pocket electronic pill reminder carried for 6 months), counseling plus alarm, and neither counseling nor alarm. Participants were followed for 18 months after HAART initiation. Primary study endpoints included plasma HIV-1 RNA and CD4 count every 6 months, mortality, and adherence measured by monthly pill count. Between May 2006 and September 2008, 400 individuals were enrolled, 362 initiated HAART, and 310 completed follow-up. Participants who received counseling were 29% less likely to have monthly adherence <80% (hazard ratio [HR] = 0.71; 95% confidence interval [CI] 0.49–1.01; p = 0.055) and 59% less likely to experience viral failure (HIV-1 RNA ≥5,000 copies/ml) (HR 0.41; 95% CI 0.21–0.81; p = 0.01) compared to those who received no counseling. There was no significant impact of using an alarm on poor adherence (HR 0.93; 95% CI 0.65–1.32; p = 0.7) or viral failure (HR 0.99; 95% CI 0.53–1.84; p = 1.0) compared to those who did not use an alarm. Neither counseling nor alarm was significantly associated with mortality or rate of immune reconstitution.
Conclusions:
Intensive early adherence counseling at HAART initiation resulted in sustained, significant impact on adherence and virologic treatment failure during 18-month follow-up, while use of an alarm device had no effect. As antiretroviral treatment clinics expand to meet an increasing demand for HIV care in sub-Saharan Africa, adherence counseling should be implemented to decrease the development of treatment failure and spread of resistant HIV.
Trial registration:
ClinicalTrials gov NCT00273780
: Please see later in the article for the Editors' Summary
Vyšlo v časopise:
A Randomized Controlled Trial Comparing the Effects of Counseling and Alarm Device on HAART Adherence and Virologic Outcomes. PLoS Med 8(3): e32767. doi:10.1371/journal.pmed.1000422
Kategorie:
Research Article
prolekare.web.journal.doi_sk:
https://doi.org/10.1371/journal.pmed.1000422
Souhrn
Background:
Behavioral interventions that promote adherence to antiretroviral medications may decrease HIV treatment failure. Antiretroviral treatment programs in sub-Saharan Africa confront increasing financial constraints to provide comprehensive HIV care, which include adherence interventions. This study compared the impact of counseling and use of an alarm device on adherence and biological outcomes in a resource-limited setting.
Methods and Findings:
A randomized controlled, factorial designed trial was conducted in Nairobi, Kenya. Antiretroviral-naïve individuals initiating free highly active antiretroviral therapy (HAART) in the form of fixed-dose combination pills (d4T, 3TC, and nevirapine) were randomized to one of four arms: counseling (three counseling sessions around HAART initiation), alarm (pocket electronic pill reminder carried for 6 months), counseling plus alarm, and neither counseling nor alarm. Participants were followed for 18 months after HAART initiation. Primary study endpoints included plasma HIV-1 RNA and CD4 count every 6 months, mortality, and adherence measured by monthly pill count. Between May 2006 and September 2008, 400 individuals were enrolled, 362 initiated HAART, and 310 completed follow-up. Participants who received counseling were 29% less likely to have monthly adherence <80% (hazard ratio [HR] = 0.71; 95% confidence interval [CI] 0.49–1.01; p = 0.055) and 59% less likely to experience viral failure (HIV-1 RNA ≥5,000 copies/ml) (HR 0.41; 95% CI 0.21–0.81; p = 0.01) compared to those who received no counseling. There was no significant impact of using an alarm on poor adherence (HR 0.93; 95% CI 0.65–1.32; p = 0.7) or viral failure (HR 0.99; 95% CI 0.53–1.84; p = 1.0) compared to those who did not use an alarm. Neither counseling nor alarm was significantly associated with mortality or rate of immune reconstitution.
Conclusions:
Intensive early adherence counseling at HAART initiation resulted in sustained, significant impact on adherence and virologic treatment failure during 18-month follow-up, while use of an alarm device had no effect. As antiretroviral treatment clinics expand to meet an increasing demand for HIV care in sub-Saharan Africa, adherence counseling should be implemented to decrease the development of treatment failure and spread of resistant HIV.
Trial registration:
ClinicalTrials gov NCT00273780
: Please see later in the article for the Editors' Summary
Zdroje
1. HarriesAD
NyanguluDS
HargreavesNJ
KaluwaO
SalaniponiFM
2001 Preventing antiretroviral anarchy in sub-Saharan Africa. Lancet 358 410 414
2. CarlucciJG
KamangaA
ShenebergerR
ShepherdBE
JenkinsCA
2008 Predictors of adherence to antiretroviral therapy in rural Zambia. J Acquir Immune Defic Syndr 47 615 622
3. OrrellC
BangsbergDR
BadriM
WoodR
2003 Adherence is not a barrier to successful antiretroviral therapy in South Africa. AIDS 17 1369 1375
4. MillsEJ
NachegaJB
BuchanI
OrbinskiJ
AttaranA
2006 Adherence to antiretroviral therapy in sub-Saharan Africa and North America: a meta-analysis. JAMA 296 679 690
5. CalmyA
PinogesL
SzumilinE
ZachariahR
FordN
2006 Generic fixed-dose combination antiretroviral treatment in resource-poor settings: multicentric observational cohort. AIDS 20 1163 1169
6. Wools-KaloustianK
KimaiyoS
DieroL
SiikaA
SidleJ
2006 Viability and effectiveness of large-scale HIV treatment initiatives in sub-Saharan Africa: experience from western Kenya. AIDS 20 41 48
7. StringerJS
ZuluI
LevyJ
StringerEM
MwangoA
2006 Rapid scale-up of antiretroviral therapy at primary care sites in Zambia: feasibility and early outcomes. JAMA 296 782 793
8. CresseyTR
JourdainG
LallemantMJ
KunkeawS
JacksonJB
2005 Persistence of nevirapine exposure during the postpartum period after intrapartum single-dose nevirapine in addition to zidovudine prophylaxis for the prevention of mother-to-child transmission of HIV-1. J Acquir Immune Defic Syndr 38 283 288
9. MartinM
Del CachoE
CodinaC
TusetM
De LazzariE
2008 Relationship between adherence level, type of the antiretroviral regimen, and plasma HIV type 1 RNA viral load: a prospective cohort study. AIDS Res Hum Retroviruses 24 1263 1268
10. BangsbergDR
2006 Less than 95% adherence to nonnucleoside reverse-transcriptase inhibitor therapy can lead to viral suppression. Clin Infect Dis 43 939 941
11. PatersonDL
SwindellsS
MohrJ
BresterM
VergisEN
2000 Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 133 21 30
12. MaggioloF
RavasioL
RipamontiD
GregisG
QuinzanG
2005 Similar adherence rates favor different virologic outcomes for patients treated with nonnucleoside analogues or protease inhibitors. Clin Infect Dis 40 158 163
13. NachegaJB
HislopM
DowdyDW
ChaissonRE
RegensbergL
2007 Adherence to nonnucleoside reverse transcriptase inhibitor-based HIV therapy and virologic outcomes. Ann Intern Med 146 564 573
14. FordN
NachegaJB
EngelME
MillsEJ
2009 Directly observed antiretroviral therapy: a systematic review and meta-analysis of randomised clinical trials. Lancet 374 2064 2071
15. NachegaJB
MillsEJ
SchechterM
Antiretroviral therapy adherence and retention in care in middle-income and low-income countries: current status of knowledge and research priorities. Curr Opin HIV AIDS 5 70 77
16. KatabiraET
OelrichsRB
2007 Scaling up antiretroviral treatment in resource-limited settings: successes and challenges. AIDS 21 Suppl 4 S5 10
17. WagnerG
RyanG
TaylorS
2007 Formative evaluation of antiretroviral therapy scale-up efficiency in sub-Saharan Africa. AIDS Patient Care STDS 21 871 888
18. FerradiniL
JeanninA
PinogesL
IzopetJ
OdhiamboD
2006 Scaling up of highly active antiretroviral therapy in a rural district of Malawi: an effectiveness assessment. Lancet 367 1335 1342
19. SevereP
LegerP
CharlesM
NoelF
BonhommeG
2005 Antiretroviral therapy in a thousand patients with AIDS in Haiti. N Engl J Med 353 2325 2334
20. BehforouzHL
FarmerPE
MukherjeeJS
2004 From directly observed therapy to accompagnateurs: enhancing AIDS treatment outcomes in Haiti and in Boston. Clin Infect Dis 38 Suppl 5 S429 436
21. RuedaS
Park-WyllieLY
BayoumiAM
TynanAM
AntoniouTA
2006 Patient support and education for promoting adherence to highly active antiretroviral therapy for HIV/AIDS. Cochrane Database Syst Rev 3 CD001442
22. SimoniJM
PearsonCR
PantaloneDW
MarksG
CrepazN
2006 Efficacy of interventions in improving highly active antiretroviral therapy adherence and HIV-1 RNA viral load. A meta-analytic review of randomized controlled trials. J Acquir Immune Defic Syndr 43 Suppl 1 S23 S35
23. PearsonCR
MicekMA
SimoniJM
HoffPD
MatedianaE
2007 Randomized control trial of peer-delivered, modified directly observed therapy for HAART in Mozambique. J Acquir Immune Defic Syndr 46 238 244
24. SarnaA
LuchtersS
GeibelS
ChersichMF
MunyaoP
2008 Short- and long-term efficacy of modified directly observed antiretroviral treatment in Mombasa, Kenya: a randomized trial. J Acquir Immune Defic Syndr 48 611 619
25. McNeilDGJ
2010 July 22 Drug war statement upstaged at AIDS gathering. The New York Times
26. McNeilDGJ
2010 May 9 As the need grows, the money for AIDS runs far short. The New York Times
27. McNeilDGJ
2010 May 10 At front lines, global war on AIDS is falling apart. The New York Times
28. FrickP
TapiaK
GrantP
NovotnyM
KerzeeJ
2006 The effect of a multidisciplinary program on HAART adherence. AIDS Patient Care STDS 20 511 524
29. FrickPA
LavreysL
MandaliyaK
KreissJK
2001 Impact of an alarm device on medication compliance in women in Mombasa, Kenya. Int J STD AIDS 12 329 333
30. ChungMH
DrakeAL
RichardsonBA
ReddyA
ThigaJ
2009 Impact of prior HAART use on clinical outcomes in a large Kenyan HIV treatment program. Curr HIV Res 7 441 446
31. OjooS
2007 Kenya national clinical manual for ART providers: a concise and practical guide to ART provision.2nd edition. Nairobi National AIDS and STI Control Program (NASCOP) 70
32. FisherJD
FisherWA
MisovichSJ
KimbleDL
MalloyTE
1996 Changing AIDS risk behavior: effects of an intervention emphasizing AIDS risk reduction information, motivation, and behavioral skills in a college student population. Health Psychol 15 114 123
33. MillerWR
RoseGS
2009 Toward a theory of motivational interviewing. Am Psychol 64 527 537
34. EmeryS
BodrugS
RichardsonBA
GiachettiC
BottMA
2000 Evaluation of performance of the Gen-Probe human immunodeficiency virus type 1 viral load assay using primary subtype A, C, and D isolates from Kenya. J Clin Microbiol 38 2688 2695
35. World Health Organization 2010 Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach. Geneva World Health Organization Press
36. PocockSJ
AssmannSE
EnosLE
KastenLE
2002 Subgroup analysis, covariate adjustment and baseline comparisons in clinical trial reporting: current practice and problems. Stat Med 21 2917 2930
37. TuldraA
FumazCR
FerrerMJ
BayesR
ArnoA
2000 Prospective randomized two-Arm controlled study to determine the efficacy of a specific intervention to improve long-term adherence to highly active antiretroviral therapy. J Acquir Immune Defic Syndr 25 221 228
38. MannheimerS
FriedlandG
MattsJ
ChildC
ChesneyM
2002 The consistency of adherence to antiretroviral therapy predicts biologic outcomes for human immunodeficiency virus-infected persons in clinical trials. Clin Infect Dis 34 1115 1121
39. SethiAK
CelentanoDD
GangeSJ
MooreRD
GallantJE
2003 Association between adherence to antiretroviral therapy and human immunodeficiency virus drug resistance. Clin Infect Dis 37 1112 1118
40. MannheimerSB
MorseE
MattsJP
AndrewsL
ChildC
2006 Sustained benefit from a long-term antiretroviral adherence intervention. Results of a large randomized clinical trial. J Acquir Immune Defic Syndr 43 Suppl 1 S41 47
41. RathbunRC
FarmerKC
StephensJR
LockhartSM
2005 Impact of an adherence clinic on behavioral outcomes and virologic response in treatment of HIV infection: a prospective, randomized, controlled pilot study. Clin Ther 27 199 209
42. PradierC
BentzL
SpireB
Tourette-TurgisC
MorinM
2003 Efficacy of an educational and counseling intervention on adherence to highly active antiretroviral therapy: French prospective controlled study. HIV Clin Trials 4 121 131
43. CoopermanNA
ArnstenJH
2005 Motivational interviewing for improving adherence to antiretroviral medications. Curr HIV/AIDS Rep 2 159 164
44. WattMH
MamanS
EarpJA
EngE
SetelPW
2009 “It's all the time in my mind”: facilitators of adherence to antiretroviral therapy in a Tanzanian setting. Soc Sci Med 68 1793 1800
45. WiseJ
OperarioD
2008 Use of electronic reminder devices to improve adherence to antiretroviral therapy: a systematic review. AIDS Patient Care STDS 22 495 504
46. SimoniJM
HuhD
FrickPA
PearsonCR
AndrasikMP
2009 Peer support and pager messaging to promote antiretroviral modifying therapy in Seattle: a randomized controlled trial. J Acquir Immune Defic Syndr 52 465 473
47. LesterRT
RitvoP
MillsEJ
KaririA
KaranjaS
2010 Effects of a mobile phone short message service on antiretroviral treatment adherence in Kenya (WelTel Kenya1): a randomised trial. Lancet 376 1838 1845
48. DonnellyJ
2001 June 7 Prevention urged in AIDS fight; Natsios says funds should spend less on HIV treatment. Boston Globe
49. AmicoKR
HarmanJJ
JohnsonBT
2006 Efficacy of antiretroviral therapy adherence interventions: a research synthesis of trials, 1996 to 2004. J Acquir Immune Defic Syndr 41 285 297
50. ChungMH
KohlerP
AttwaM
ThigaJ
John-StewartGC
2010 Comparing clinic retention between residents and nonresidents of Kibera, Kenya. J Acquir Immune Defic Syndr 53 422 424
51. OsterbergL
BlaschkeT
2005 Adherence to medication. N Engl J Med 353 487 497
52. GillCJ
HamerDH
SimonJL
TheaDM
SabinLL
2005 No room for complacency about adherence to antiretroviral therapy in sub-Saharan Africa. AIDS 19 1243 1249
53. MellorsJW
RinaldoCRJr.
GuptaP
WhiteRM
ToddJA
1996 Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 272 1167 1170
54. AldousJL
HaubrichRH
2009 Defining treatment failure in resource-rich settings. Curr Opin HIV AIDS 4 459 466
55. HosseinipourMC
van OosterhoutJJ
WeigelR
PhiriS
KamwendoD
2009 The public health approach to identify antiretroviral therapy failure: high-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy. AIDS 23 1127 1134
Štítky
Interné lekárstvoČlánok vyšiel v časopise
PLOS Medicine
2011 Číslo 3
- Parazitičtí červi v terapii Crohnovy choroby a dalších zánětlivých autoimunitních onemocnění
- Pleiotropní účinky statinů na kardiovaskulární systém
- Statiny indukovaná myopatie: Jak na diferenciální diagnostiku?
- Zástava srdce u pacienta se střelnými ranami – kazuistika
- Statinová intolerance
Najčítanejšie v tomto čísle
- The BCG World Atlas: A Database of Global BCG Vaccination Policies and Practices
- How Can Institutional Review Boards Best Interpret Preclinical Data?
- The Challenge of Discharging Research Ethics Duties in Resource-Constrained Settings
- HIV-1 Drug Resistance Emergence among Breastfeeding Infants Born to HIV-Infected Mothers during a Single-Arm Trial of Triple-Antiretroviral Prophylaxis for Prevention of Mother-To-Child Transmission: A Secondary Analysis